SCHEMBL11195440

SCHEMBL11195440

OCc1cccc(Oc2cccc(C(F)(F)F)c2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 1/20 0.50
PRKCD Q05655 1/20 0.50
PPARG P37231 1/20 0.50
PPARA Q07869 1/20 0.50
MRGPRX4 Q96LA9 1/20 0.49
FAAH O00519 1/20 0.48
CETP P11597 1/20 0.48
FDFT1 P37268 1/20 0.48
MAPK14 Q16539 1/20 0.48
IDO1 P14902 2/20 0.47
NR1H2 P55055 2/20 0.47
NR1H3 Q13133 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
LTA4H P09960 1/20 0.47
EPAS1 Q99814 1/20 0.46
NR4A2 P43354 1/20 0.46
ALDH1A1 P00352 1/20 0.46
POLB P06746 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
KDM4E B2RXH2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1011408 0.89 MAPK14 (0.50) MRGPRX4CETPFDFT1MAPK14NR1H2
SCHEMBL875576 0.89 LTA4H (0.58) PRKCAPRKCDPPARGPPARAMRGPRX4
SCHEMBL2257 0.84 TAAR1 (0.60) PRKCAPRKCDIDO1ALDH1A1KDM4E
SCHEMBL9798371 0.84 LTA4H (0.54) IDO1LTA4HALDH1A1POLBL3MBTL1
SCHEMBL5543857 0.83 FAAH (0.51) PPARGPPARAMRGPRX4FAAHCETP
SCHEMBL920369 0.83 MAOB (0.57) PPARGPPARAMRGPRX4FAAHFDFT1
SCHEMBL13237463 0.83 IDO1 (0.51) PPARGPPARAMRGPRX4FDFT1MAPK14
SCHEMBL6354530 0.83 CETP (0.48) PPARGPPARAMRGPRX4FAAHCETP
SCHEMBL875557 0.82 EPAS1 (0.52) PRKCAPRKCDPPARGPPARAMRGPRX4
SCHEMBL883499 0.82 EPAS1 (0.49) PRKCAPRKCDPPARGPPARAMRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968552-B2 Oxadiazolidinedione compound ASTELLAS PHARMA INC. (JP) 2011-06-28 US disclosed
US-7968552-B2 Oxadiazolidinedione compound ASTELLAS PHARMA INC. (JP) 2011-06-28 US disclosed
US-20090186909-A1 Oxadiazolidinedione Compound ASTELLAS PHARMA INC. (JP) 2009-07-23 US disclosed
US-20090186909-A1 Oxadiazolidinedione Compound ASTELLAS PHARMA INC. (JP) 2009-07-23 US disclosed
US-7541466-B2 Tetrahydroisoquinoline derivatives for treating protein trafficking diseases GENZYME CORPORATION (US) 2009-06-02 US disclosed
US-4411912-A Insecticidal isovaleric acid esters ZOECON CORPORATION (US) 1983-10-25 US disclosed
US-4366325-A Process for the preparation of 3-phenoxy-benzaldehydes BAYER AKTIENGESELLSCHAFT (DE) 1982-12-28 US disclosed
EP-0028714-B1 PROCESS FOR THE PREPARATION OF 3-PHENOXYBENZALDEHYDES BAYER AG (DE) 1982-09-15 EP disclosed
US-4243819-A Substituted amino acids ZOECON CORPORATION (US) 1981-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186909-A1 Oxadiazolidinedione Compound GPR119, GPR39, GPR65 PRKCA 1971/4885PRKCD 1545/4885PPARG 224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.